Hull R D, Pineo G F
Department of Medicine, University of Calgary, Alberta, Canada.
Hematol Oncol Clin North Am. 1992 Oct;6(5):1095-103.
The accumulating evidence indicates that certain LMW-heparins administered subcutaneously may replace classical intravenous heparin therapy. Certain of these subcutaneously administered LMW-heparins do not require monitoring. The simplified care offered by LMW-heparin therapy offers the possibility of transferring care from in the hospital to out of the hospital in uncomplicated patients with deep vein thrombosis. The advantages to the patient of avoiding in-hospital care and its associated hazards are obvious. Outpatient LMW-heparin therapy will likely prove to be highly cost-effective. It is uncertain at the present time whether the findings associated with an individual LMW-heparin preparation can be extrapolated to a different LMW-heparin. For this reason the findings of clinical trials apply only to the particular LMW-heparin evaluated and cannot be generalized to the LMW-heparins at large.
越来越多的证据表明，某些皮下注射的低分子肝素可能会取代传统的静脉肝素治疗。其中某些皮下注射的低分子肝素不需要监测。低分子肝素治疗提供的简化护理为深静脉血栓形成的非复杂患者将护理从医院转移到院外提供了可能性。避免住院护理及其相关风险对患者的益处显而易见。门诊低分子肝素治疗可能会被证明具有很高的成本效益。目前尚不确定与一种低分子肝素制剂相关的研究结果是否可以外推至另一种不同的低分子肝素。因此，临床试验的结果仅适用于所评估的特定低分子肝素，不能推广至所有低分子肝素。
